Dianthus Therapeutics (DNTH) EBITDA Margin (2022 - 2025)
Historic EBITDA Margin for Dianthus Therapeutics (DNTH) over the last 4 years, with Q3 2025 value amounting to 9267.68%.
- Dianthus Therapeutics' EBITDA Margin fell 81417100.0% to 9267.68% in Q3 2025 from the same period last year, while for Sep 2025 it was 4121.6%, marking a year-over-year decrease of 28768600.0%. This contributed to the annual value of 1361.83% for FY2024, which is 1720400.0% up from last year.
- As of Q3 2025, Dianthus Therapeutics' EBITDA Margin stood at 9267.68%, which was down 81417100.0% from 16477.2% recorded in Q2 2025.
- Over the past 5 years, Dianthus Therapeutics' EBITDA Margin peaked at 676.39% during Q3 2022, and registered a low of 16477.2% during Q2 2025.
- In the last 4 years, Dianthus Therapeutics' EBITDA Margin had a median value of 1581.46% in 2024 and averaged 3247.59%.
- In the last 5 years, Dianthus Therapeutics' EBITDA Margin surged by 4701400bps in 2024 and then plummeted by -155315800bps in 2025.
- Dianthus Therapeutics' EBITDA Margin (Quarter) stood at 861.87% in 2022, then tumbled by -186bps to 2467.61% in 2023, then grew by 11bps to 2188.16% in 2024, then tumbled by -324bps to 9267.68% in 2025.
- Its EBITDA Margin stands at 9267.68% for Q3 2025, versus 16477.2% for Q2 2025 and 2523.39% for Q1 2025.